Analyst: The sum is bigger than the individual parts for ALK
A possible approval of the vaccine, Mitizax, against house dust mite allergy, following presentation of positive data earlier in the week, could boost sales of another allergy product from ALK – the grass pollen allergy vaccine Grazax.
by Stefan Singh Kailay
ALK-Abello’s announcement earlier in the week concerning positive results for the Danish company’s vaccine against house dust mite allergy, Mitizax, was good news in itself, but there might be even more reason to rejoice following the news, says Sydbank-analyst Søren Løntoft Hansen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75)
